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Localization of cyclophilin A and cyclophilin C mRNA in murine
kidney using RT-PCR. Cyclosporin A (CsA), which is widely used as an
immunosuppressant, has a nephrotoxic side effect. The mechanism of
this nephrotoxicity is not well understood; however, recent studies
suggest that cyclophilin (cyp) is responsible for mediating the immuno-
suppressive action of CsA through the interaction with the Ca2- and
calmodulin-dependent phosphatase, calcineurin. While cyp A mRNA is
expressed ubiquitously, cyp C mRNA has been shown to be topically
expressed, including in the kidney. We examined: (1) distribution of cyp
A and cyp C mRNA in microdissected murine nephron segments, using
a combination of reverse transcription and polymerase chain reaction
(RT-PCR) techniques, and (2) the effect of CsA administration on cyp C
mRNA expression in proximal convoluted tubule. Among the nephron
segments examined, large signals for cyp C PCR product were detected
in proximal convoluted tubule and proximal straight tubule. Our data
showed that the distribution of cyp C mRNA was uneven, and it mainly
existed in segments that are relatively sensitive to CsA toxicity. In
contrast, cyp A mRNA was found to be distributed almost equally along
the nephron segments examined. By CsA administration, the signal for
cyp C mRNA PCR product was increased. These results suggest that
cyp C may play some role in the renal tubular disorder observed in CsA
nephrotoxicity.
Cyclophilin (cyp) was originally identified as a specific bind-
ing protein for cyclosporin A (CsA) [1, 2]. Several isoforms of
cyp have been discovered in human and other species. CsA is
an undecapeptide fungal product, which is widely used to
prevent allograft rejection [31 and has been used in the treat-
ment of a variety of autoimmune diseases [4]. Cyp, as the
receptor for CsA, is supposed to be the mediator of the
immunosuppressive action of CsA.
The major limitation to the clinical use of CsA is its nephro-
toxicity. The mechanism of this toxicity is obscure. Friedman
and Weissman reported that mRNA encoding cyp C, a newly
identified cyp, is topically expressed, including in the kidney
[5]. Therefore, it appears that cyp C may be a candidate for
involvement in CsA-induced renal damage.
Recently, Moriyama et a! [6] introduced a new method for
measurement of relative levels of specific mRNA in single
Received for publication March 15, 1993
and in revised form December 10, 1993
Accepted for publication December 13, 1993
© 1994 by the International Society of Nephrology
microdissected renal tubules, using the polymerase chain reac-
tion (PCR) coupled to reverse transcription (RT-PCR).
In the present study, we examined: (1) the difference in the
microdistributions of cyp A and cyp C mRNA in nephron
tubules using RT-PCR, and (2) the effect of CsA administration
on cyp C mRNA expression in proximal convoluted tubule
(PCT).
Methods
Renal tubule microdissection
Male ICR mice aged eight weeks were sacrificed by decapi-
tation. The left kidney was perfused initially with 10 ml of
ice-cold dissection solution (solution 1), and then with 10 ml of
the same solution containing 1 mg/mI collagenase (collagenase
solution) (type I, 300 U/mg Sigma Chemical, St. Louis, Mis-
souri, USA) and 1 mg/mi bovine serum albumin (Sigma Chem-
ical Co.). The dissection solution (solution 1) contained the
following (in mM): 135 NaC1, 1 Na2SO4, 1.2 MgSO4, 5 KC1, 2
CaCI2, 5.5 glucose, and 5 HEPES (pH 7.4). The left kidney was
removed and a coronal section containing the entire corticopap-
illary axis was made. This section was cut into three pieces:
cortex, outer medulla, and inner medulla. These pieces were
transferred into individual tubes containing 1 ml of the same
collagenase solution used to perfuse the kidney. The tubes were
incubated for 40 minutes (cortex and outer medulla) or 60
minutes (inner medulla) at 37°C in a shaking water bath. The
solutions were bubbled with 100% oxygen during these incuba-
tions. Then tissues were transferred to the dissection solution
containing 10 mM vanadyl nbonucleotide complex (Life Tech-
nologies, Inc., Gaithersburg, Maryland, USA), a potent RNase
inhibitor, and they were placed on ice until microdissection.
Following the previously described procedures [6, 7], we
microdissected the following structures: PCT, proximal straight
tubule (PST), medullary thick ascending limb (MTAL), cortical
collecting duct (CCD), outer medullary collecting duct
(OMCD), inner medullary collecting duct (IMCD), and arcuate
artery.
The length of the dissected tubules was measured using a
calibrated eyepiece micrometer. Generally, 2 mm lengths of
renal tubule segment or arcuate artery were transferred to each
assay tube, as indicated.
Microdissected structures were transferred to separate wash
dishes containing 10 ml of the dissection solution. Microdis-
sected tubules were washed free of contaminating debris and
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the vanadyl ribonucleotide complex. They were then trans-
ferred into the appropriate RT-PCR reaction tube, which con-
tained 10 pJ of ice-cold dissection solution containing 1 U/j.d of
human placental RNase inhibitor (Boehringer Mannheim,
GmbH, Mannheim, Germany) and 5 mM dithiothreitol (DTT,
Sigma Chemical Co.).
Reverse transcription
Reverse transcription (RT) was performed using a cDNA
synthesis kit (Boehringer Mannheim GmbH). The RNase inhib-
itor solution was removed, and 9 d of Triton X-l00, containing
> 1 U/pt RNase inhibitor and 5 mrvi DTT, was added to
permeabilize the cells. RT components were added to the
reaction tubes as described previously [6, 71: 4 jsl of buffer I, 1
sl of RNase inhibitor, 2 d of deoxynucleotide mixture, 2 tl of
random primer, and 2 d of avian myeloblastoma virus reverse
transcriptase. Reaction tubes were incubated at 42°C for 60
minutes in a Programmed Tempcontrol System (Astec, Tokyo,
Japan). At the end of the incubation period, the reaction was
stopped by heating at 90°C for five minutes. This heat treatment
also denatures RNA-cDNA hybrids and inactivates the reverse
transcriptase.
Polymerase chain reaction
Polymerase chain reaction (PCR) was performed using the
GeneAmp DNA Amplification Reagent Kit (Perkin-Elmer Ce-
tus, Norwalk, Connecticut, USA), with mouse cyp C-specific
primers prepared on a DNA synthesizer (Applied Biosystems,
Inc., Tokyo, Japan). We designed specific primers with high
calculated Tm (>75°C), which allows a stringent annealing
temperature in the PCR cycle. Cyp C primer 1 (antisense) was
defined by bases 662 to 681, and primer 2 (sense) encompassed
bases 103 to 122 [5]. The sequence of primer 1 was 5'-
GGGACCTCAACCACAAAGGG-3'; primer 2 was 5'-GAGC-
CCTGGTGTCTTCTTCG-3'. The predominant cDNA amplifi-
cation product was predicted to be 578 bp in length (the distance
between primers plus primer length). A third oligonucleotide
was synthesized to serve as an amplification product-specific
probe, This oligonucleotide (sense) included bases 636 to 655 of
the cDNA, positioned between primer 1 and primer 2. The
sequence of this oligonucleotide probe was 5'-ACAGTG-
GCAAGATAGATGTG-3'.
Cyp A primer 1 (antisense) was defined by bases 489 to 508,
and primer 2 (sense) encompassed bases 99 to 118 [8]. The
sequence of primer 1 was 5'-ATCTTCTFGCTGGTCTTGCC-
3'; primer 2 was 5'-GTCTCCTTCGAGCTGITT'GC-3'. The
predominant cDNA amplification product was predicted to be
410 bp in length. A third oligonucleotide was synthesized to serve
as an amplification product-specific probe. This oligonucleotide
(antisense) included bases 453 to 472 of the cDNA, positioned
between primer 1 and primer 2. The sequence of this oligonucle-
otide probe was 5'-ATFGTGGAAGCCATGGAGCG-3'.
To carry out the PCR, 80 tl of a PCR Master mix was added
to each tube directly. Fifty picomoles each of primers 1 and 2
were used per reaction. Deoxynucleotides were added to a final
concentration of 0.20 m each. Reaction buffer (lOx) was
diluted (1/10) to have a final composition of 10 mrt Tris-HCI, pH
8.3,50 mrt KC1, 1.5 mrvi MgCl2, 0.001% (wt/vol) gelatin, and 2.5
units of Taq DNA polymerase.
One hundred microliters of mineral oil were overlaid to
prevent evaporation during the high temperature incubations.
The tubes were placed in a Programmed Tempcontrol system as
follows: incubation at 94°C for three minutes (initial melt); then,
33 cycles of the following sequential steps: 94°C for one minute
(melt), 60°C for one minute (anneal), and 72°C for three minutes
(extend); and finally, incubation at 72°C for seven minutes (final
extension).
GsA administration
CsA was injected to the mice intraperitonealy for six days at
a daily dosage of 50 mg/kg. On the seventh day, the mice were
sacrificed and PCT was microdissected from the kidney with
the method described in this paper. RT-PCR for cyp C was
performed from PCT from CsA treated mice and control. In this
experiment, 30 PCR cycles were performed to obtain the
appropriate amount of PCR products and to preserve better
linearity between the amount of starting material and the
amplification products. This experiment was done with five
pairs (CsA treated and control) of mice.
PCR product analysis
Ninety microliters of the total reaction volume were ethanol-
precipitated [10]. The PCR products were size-fractionated by
agarose gel electrophoresis. After electrophoresis and ethidium
bromide staining, DNA bands were visualized with an ultravi-
olet transilluminator (Funakoshi, Tokyo, Japan).
For Southern blot analysis, gels were denatured and blotted
onto a nitrocellulose filter (Funakoshi) essentially as described
by Maniatis, Fritsch and Sambrook [10]. The synthetic oligo-
nucleotide probes were end-labeled with 32P as described
previously [7]. Prehybridization/hybridization washes were also
the same as previously described [7].
Results
Effect of reverse transcription on cyp C and cyp A mRNA
ampljfication
With reverse transcription, we detected a clear single band,
that was the predicted size of 578 bp for cyp C from PCT, and
we also detected a clear single band that was the predicted size
of 410 bp for cyp A from PCT (Fig. 1 A, C). When the PCR
procedure was carried out in the absence of reverse tran-
scriptase, the 578 bp band and the 410 bp band were not seen,
and there was no other recognizable band. This indicated that
the 578 and the 410 bp bands originated from mRNA, not from
genomic DNA. The Southern blots of the gels demonstrated
that cyp C-specific probe binds to the 578 bp product, and that
cyp A-specific probe binds to the 410 bp product, confirming
their identities (Fig. 1 B, D).
Distribution of cyp C mRNA in microdissected structures
Each reaction was performed using 2 mm of tubule length or
arcuate artery. A single band of predicted size (578 bp) was
consistently found from PCT, PST, MTAL, CCD, OMCD,
IMCD, and arcuate artery (Fig. 2A). The Southern blots of the
gel demonstrated specific binding of the oligonucleotide probe
to the 578 bp product (Fig. 2B). A large signal was found in PCT
and PST. Small but detectable signals were observed from
MTAL, CCD, OMCD, IMCD, and arcuate artery.
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Fig. 2. Detection of cyp C mRNA in microdissected renal structures by
RT-PCR. A. Ethidium-bromide-stained agarose gel for cyp C mRNA.
The arrow indicates expected PCR product size (578 bp). B. Autorad-
iograms of corresponding Southern blots. The blots were probed with a
32P-labeled oligonucleotide localized between the PCR primers. Abbre-
viations are: PCT, proximal convoluted tubule; PST, proximal straight
tubule; MTAL, medullary thick ascending limb; CCD, cortical collect-
ing duct; OMCD, outer medullary collecting duct; IMCD, inner med-
ullary collecting duct; AA, arcuate artery.
Fig. 1. Effect of RT on cyp C and cyp A mRNAs amplification. A.
Ethidium-bromide-stained agarose gel for cyp C mRNA. The arrow
indicates expected PCR product size (578 bp). B. Autoradiograms of
corresponding Southern blots. The blots were probed with a 32P-Iabeled
oligonucleotide localized between the PCR primers. C. Ethidium-
bromide-stained agarose gel for cyp A mRNA. The arrow indicates
expected PCR product size (578 bp). D. Autoradiograms of correspond-
ing Southern blots. The blots were probed with a 32P-labeled oligonu-
cleotide localized between the PCR primers. In each panel, the left lane
is the PCR carried out without RT, the right lane is the PCR carried out
with RT.
We performed these experiments six times. The results
showed that large signals were consistently found in PCT and
PST (Table 1).
Distribution of cyclophilin A mRNA in microdissected
structures
The band for cyp A PCR product was detected almost equally
in all of the nephron segments examined (Fig. 3A). The South-
ern blots of the gels demonstrated specific binding of the
oligonucleotide probe to the 410 bp product (Fig. 3B). Almost
equal signals were obtained from the segments.
Effect of CsA administration
The bands for cyp C PCR product were detected in the PCT
of both the CsA treated mice and control (Fig. 4). The signal of
PCT from the CsA treated mice was larger than that of the PCT
from control. We performed this experiment five times and
confirmed this result.
Discussion
Our study shows that mRNA encoding murine cyp C can be
found throughout the nephron and arcuate artery. Among the
Table 1. Distribution of cyp C mRNA in microdissected renal
structures using RT-PCR
Experiment
no.
Nephron segments
PCT PST MTAL CCD OMCD IMCD AA
I ++ ++
2 + +
3 ++ + ND
4 ++ + ND
5 + ++ — + + ND
6 + + — ND
Abbreviations are: PCT, proximal convoluted tubule; PST, proximal
straight tubule; MTAL, medullary thick ascending limb; CCD, cortical
collecting duct; OMCD, outer medullary collecting duct; IMCD, inner
medullary collecting duct; AA, arcuate artery. The intensity of the
autoradiogram spot for each segment is classified into: (-i- +) strong; (+)
intermediate; (±) weak; and (—) not detectable; ND, not done.
structures examined, expression is high in PCT and PST. This
mode of distribution is quite different from that of cyp A
mRNA, which is almost equally expressed along the nephron
segments examined. The cyp C mRNA expression is increased
by CsA administration.
As will be discussed later, cyp is supposed to mediate the
immunologic action of CsA. It is of interest to investigate
whether cyp plays any role in the nephrotoxic action of CsA.
The nephrotoxicity of CsA roughly consists of two different
patterns. One is an acute hemodynamic and reversible pattern,
which often occurs soon after onset of CsA treatment. The
other pattern of toxicity is chronic and irreversible; it is seen
with longer-term CsA treatment and is associated with morpho-
logic changes. Several explanations have been offered to ac-
count for the CsA nephrotoxicity, including stimulation of the
RI (—) (+)
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Fig. 3. Detection of cyp A mRNA in microdissected renal structures by
RT-PCR. A. Ethidium-bromide-stained agarose gel for cyp A mRNA.
The arrow indicates the expected PCR product size (410 bp). B.
Autoradiograms of corresponding Southern blots. The blots were
probed with a 32P-labeled oligonucleotide localized between the PCR
primers, Abbreviations are: PCT, proximal convoluted tubule; PST,
proximal straight tubule; MTAL, medullary thick ascending limb; CCD,
cortical collecting duct; OMCD, outer medullary collecting duct;
IMCD, inner medullary collecting duct; AA, arcuate artery.
renin-angiotensin system [11], activation of tubuloglomerular
feedback [12], abnormalities in renal arachidonic acid metabo-
lism [13, 14], and increased production of endothelin [15].
However, the mechanism(s) of the nephrotoxicity is not fully
understood. Cyp C mRNA is topically expressed, including in
the kidney [5]. This gives rise to the possibility that cyp C is
involved in CsA nephrotoxicity. Meanwhile, it does not seem
likely that cyp A plays a major role in this toxicity, because cyp
A mRNA expression is abundant and ubiquitous [161.
There have been some reports about the morphology associ-
ated with CsA nephrotoxicity. Mihatsch et a! [17] demonstrated
tubular inclusion bodies corresponding to autolysosomes and
giant mitochondria, tubular vacuolization due to dilation of
endoplasmic reticulum, tubular microcalcification, and tubular
regeneration limited to or predominating in the proximal tubule.
Bertani et at [18] reported isometric vacuolization and loss of
the brush border involving proximal tubular cells in the early
phase, followed by a peculiar lesion in distal tubular cells due to
glycogen accumulation. Thliveris et at [19] documented numer-
ous vacuoles, lysosomal-like structures, and loss of cellular
integrity in proximal and distal tubules. Finally, Wilson and
Hartz [20] indicated that cultured cells from proximal convo-
luted tubule and proximal straight tubule epithelia were sensi-
tive to the toxic effect of CsA. There are some dissimilarities
among these reports, due presumably to the differences in
animal models, CsA dose, and duration and route of adminis-
tration. There is, however, the common feature of predominant
proximal tubule injury. Our data indicate that cyp mRNA
expression is high in PCT and PST, and this seems to be
compatible with the idea that cyp C plays some role in CsA
nephrotoxicity, taking into account this common morphologic
feature. When CsA is administered, it may be bound and
trapped more within PCT and PST, which are enriched with cyp
content, and may be prevented from cellular elimination. This
Fig. 4. Effect of CsA administration on cyp C mRNA expression. A.
Ethidium-bromide-stained agarose gel for cyp C mRNA. The arrow
indicates expected PCR product size (578 bp). B. Autoradiograms of
corresponding Southern blots. The blots were probed with a 32P-labeled
oligonucleotide localized between the PCR primers. Lane 1: PCT from
control mouse; Lane 2: PCT of CsA treated mouse.
leads to increased toxic action of CsA on proximal tubule cells.
Because CsA binds to cyp C, the amount of unbound cyp C,
which plays some physiological roles, was depleted. Thus, the
amount of cyp C mRNA expression could increase with some
feedback mechanism(s). Our result from the CsA treated exper-
iment is consistent with the idea of "CsA-cyp C linking."
However, the possibility cannot be excluded that some other
factor which is still unknown may also be responsible for the
toxicity. With regard to this, Stillman et at [21] reported that
CsA induces atrophic and hypertrophic changes in MTAL, a
structure in which cyp C mRNA expression is low according to
our results. Recently, CsA-induced inhibition of Na ,K-
ATPase activity in the CCD, MTAL, and OMCD from the outer
stripe was reported [22]. This finding can well explain the
clinical hyperkalemia and hypomagnesemia observed in pa-
tients treated with CsA [22].
Cyp was proved to be identical to peptidyl-prolyl cis-trans
isomerase (PPIase) [23, 24]. This PPIase activity is inhibited
when cyp binds to CsA. Cyp-CsA complex competitively binds
to and inhibits the Ca2- and calmodulin-dependent phos-
phatase calcineurin [25]. Therefore, the hypothesis has been
forwarded that cyp may play some role in the pharmacological
action of CsA, that is, its immunosuppressive effect and neph-
rotoxicity, through the PPIase activity of cyp and/or phos-
phatase activity of calcineurin. The speculation that the action
of CsA develops through the inhibition of PPIase is challenged
by several findings, however. First, cyps were found intracel-
lularly at concentrations far above the concentration of CsA
required for immunosuppression [26, 27]. Second, several CsA
analogues were reported with cyp-binding affinities and immu-
nosuppressive activities that did not correlate [28]. Third,
FKBP, the binding protein for another immunosuppressant,
FK506, also has PPIase, and even when PPIase activity of cyp
is inhibited by binding to CsA, its enzyme activity is intact [29].
On the contrary, several studies have supported the hypothesis
that calcineurin is the second target of CsA, which acts through
its primary cyp target. Transfection of a calcineurin catalytic
subunit increases the 50% inhibitory concentration (IC50) of
CsA [30]. Calcineurin activates the interleukin-2 promoter in a
CsA-sensitive manner [301. CsA prevents T cell proliferation by
a e a as a
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inhibiting the induction of interleukin-2 transcription [311. Fur-
thermore, overexpression of calcineurin in the T cell line Jurkat
increases resistance to CsA [32]. And finally, at low concentra-
tion, CsA enhances the phosphorylation of endogenous protein
substrates in rat brain tissue and PC12 cells (a neuronal-like cell
line) [33]. Therefore, it appears that calcineurin may interact
with CsA and Cyp, and reduce the Ca2-dependent phosphor-
ylation of endogenous protein substrates. The inhibition of
phosphatase activity of calcineurin by CsA-cyp complex re-
duces the dephosphorylation of substrate proteins, some of
which must be essential to maintaining cell function, and this
effect may lead to cell injury. Cyp C, which is largely expressed
in PCT and PST, may produce the toxic effect of CsA by
inhibiting the phosphatase activity of calcineurin in these seg-
ments.
We chose a simple approach, RT-PCR, to relative quantita-
tion rather than any of the complicated alternatives for the
following reason. The value of knowing the absolute number of
mRNA molecules present in a given cell may be extremely
limited for most physiological questions, because there is
presently no way to relate this number to the ultimate functional
expression of the gene product. We believe that our method
gives a relative measure of the amount of cyp A and cyp C
mRNA initially present in the cells. This conclusion is based on
the observation that there is an approximately linear relation-
ship between the tubular length used for the assay (that is, the
amount of starting material) and the value obtained from
densitometry of the amplification product band [34].
In summary, mRNA encoding murine cyp C can be found
from PCT to IMCD along the nephron and arcuate artery.
Among the structures examined, cyp C mRNA expression is
uneven, and it exists mainly in PCT and PST, which are
relatively sensitive to CsA toxicity, particularly its chronic
form. Cyp A mRNA expression is almost equal along the renal
tubule segments examined. Cyp C mRNA expression in PCT
from the CsA treated mice was increased. These results suggest
that cyp C may play some role in the renal tubular disorder
observed in CsA nephrotoxicity.
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